News

May 3, 2024

Medvasc’s patent portfolio  granted in all prioritized jurisdictions

During 2023 MedVasc patent was granted in China, India, Canada, and Brazil. MedVasc’s patent portfolio is strengthened by the progression relating to the company’s medical device, the anesthesia catheter SolutioTM. SolutioTM minimizes the pain when performing the gold standard treatment methods for treating varicose veins and is expected to…
May 3, 2024

SolutioTM featured twice at 2023 Veith Symposium, NYC

MedVasc anesthesia catheter SolutioTM gained attention during 2023 Veith Symposium in NYC as renowned KOL Dr. Lowell Kabnick gave a talk on center stage about next-generation venous devices. In addition, Dr. Michael Åkesson was also invited to present the results from our first-in-man clinical study….
August 30, 2023

MedVasc selected to join accelerator powered by Medtronic

MedVasc has been selected to join prestigious medtech ac  MedVasc has been selected as 1 of 11 international medtech startups to learn from Medtronic and MedLim partners how to accelerate commercialization.  It all kicked off with a fantastic week in Maastricht followed by digital sessions and 1-1 meetings.  “We feel humble and grateful for the opportunity. It’s been a…
August 30, 2023

Successful closing of SEK 3 million investment round

MedVasc has closed an investment round of 3 M SEK. The investors include several Life science investors such as Life Science Invest Gamma, but also existing and new private investors. The raised capital will mainly be used for final product development and for preparing an FDA 510k application for…
January 20, 2023

Medvasc’s patent portfolio has been granted in key licensing markets

In the fall of 2022, the patent authorities of India, Canada, and Brazil announced that they intend to grant MedVasc’s patent. MedVasc’s patent portfolio is strengthened by the announcements relating to the company’s medical device, the anesthesia catheter SolutioTM. SolutioTM minimizes the pain when performing the gold standard treatment…

For press inquiries, please send an email

Subscribe to our newsletter

For more information on how we process your personal data please see our Privacy Notice